Home » FDA Issues Extensive Update About Revlimid, Second Cancers
FDA Issues Extensive Update About Revlimid, Second Cancers
The U.S. Food and Drug Administration issued an extensive update regarding the risk of developing a second cancer while being treated with Revlimid. The update comes on the heels of a change the FDA made to the prescribing information for Revlimid (lenalidomide) in March of this year.
The Myeloma Beacon
The Myeloma Beacon
Upcoming Events
-
07May
-
14May
-
30May